What the 2nd Basic Plan Actually Locked In
On July 21, 2026, Korea approved the 2nd Basic Plan for Advanced Regenerative Medicine and Advanced Biopharmaceuticals (2026–2030). The plan rests on three strategies: expanding patient access, rationalizing science-based regulation while strengthening safety oversight, and building technological and industrial competitiveness.
Where the first plan centered on research support, the second shifts its weight to *treatment* and *industrial infrastructure*. The market has moved just as fast: companies participating in Korea's advanced regenerative medicine sector grew from 76 in 2023 to 138 in 2025 — roughly 80% growth. For late entrants, that means tougher competition, but also a much deeper pool of potential collaborators.
Low-Risk Clinical Research Reform — How Much Lower Is the Bar?
The change companies will feel most is the reduced non-clinical data burden for low- and medium-risk clinical research. Required submissions will be differentiated by cell type, and existing published literature will be accepted in place of certain data packages.
Most significantly, studies reclassified as low-risk may apply for treatment plan review without a preceding clinical study. A pathway that previously took two to three years can be meaningfully compressed.
The relief is not automatic, however. Use these checkpoints to locate your own pipeline:
Minimal manipulation plus homologous use points strongly toward low-risk classification. Any gene modification will likely push the program into the high-risk category.
Redesigning Your Pipeline for the 2028 Treatment Market
The government is advancing multicenter clinical research across four indications, including knee osteoarthritis and intractable chronic pain, with domestic cell-culture treatment potentially available as early as the second half of 2028.
That shift redirects patient demand currently flowing overseas back into Korea — and it translates directly into demand for cell processing facilities (CPF) and contract manufacturing. Even companies that are not developing therapies themselves will find openings in facilities, process engineering, and quality operations.
When selecting indications, weigh two distinct tracks:
From KRW 90B to KRW 200B in R&D — Where to Attach Yourself
The plan commits to expanding national R&D investment to over KRW 200 billion per year by 2030, targeting 150 cumulative clinical research and treatment plan approvals and at least five domestically developed advanced biopharmaceuticals.
As calls for proposals expand, three tracks favor smaller companies:
Most importantly, an approved clinical research plan functions as the credential that unlocks the next grant and the next funding round. A single first approval can be worth more than early revenue.
Practical Preparation Checklist
How KITIM Supports You
The Korea Institute of Technology Innovation Management (KITIM) supports small and mid-sized companies in advanced regenerative medicine with regulatory strategy and government program entry:
The five-year window opened by this plan will reward only the companies that prepare for it. If you want clarity on where your pipeline sits and what your response roadmap should look like, contact a KITIM consultant today. We will work alongside you from initial assessment through proposal submission and certification.